Manami Oya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manami Oya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Audrys G. Pauza
Department of Physiology, Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand
1 shared publication Dainius H. Pauza
Institute of Anatomy, Faculty of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania (D.H.P.).
1 shared publicationDavid J. Hodson
Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford, United Kingdom (D.J.H.).
1 shared publication- David Murphy
Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, University of Bristol, Dorothy Hodgkin Building, Bristol, United Kingdom
1 shared publication - Fiona Dianne McBryde
Manaaki Manawa – the Centre for Heart Research, Department of Physiology, Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand
1 shared publication - Igor Simões Assunção Felippe
The Centre for Heart Research – Manaaki Mānawa, Department of Physiology, Faculty of Health & Medical Sciences, University of Auckland, Grafton Campus, Auckland, 1023, New Zealand
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (7) , 967-982
Melanocortin System Activates Carotid Body Arterial Chemoreceptors in Hypertension
BACKGROUND: The internal milieu of the body is controlled by a system of interoceptors coupled to motor outflows that drive compensatory adaptive responses. These include the arterial chemoreceptors, best known for sensing arterial oxygen. In cardiometabolic diseases, such as essential hypertension, the carotid bodies (CB) exhibit heightened reflex sensitivity and tonic activity without an apparent stimulus. The mechanisms behind CB sensitization in these conditions are not well understood. METHODS: Guided by functional genomics, a range of functional assays is used to interrogate downstream intracellular and interorgan signaling pathways involved in arterial chemosensory function. RESULTS: Here, we report the presence of the MC4R (melanocortin 4 receptor) in the mammalian CB and show its elevated expression in experimental hypertension. We demonstrate that melanocortin agonists activate arterial chemosensory cells, modulating CB chemosensory afferent drive to influence chemoreflex-evoked sympathetic and ventilatory activity. Transcriptional analysis of hypertensive CB implicates the activation of the Mash1 (mammalian achaete-scute homolog 1; Ascl1 ) regulatory network in driving elevated Mc4r expression. CONCLUSIONS: Collectively, our data indicate a primarily pathophysiological role of melanocortin signaling in arterial chemosensation, contributing to excess sympathetic activity in cardiometabolic disease.
- 12 September 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (7) , 967-982
Open AccessMelanocortin System Activates Carotid Body Arterial Chemoreceptors in Hypertension
BACKGROUND: The internal milieu of the body is controlled by a system of interoceptors coupled to motor outflows that drive compensatory adaptive responses. These include the arterial chemoreceptors, best known for sensing arterial oxygen. In cardiometabolic diseases, such as essential hypertension, the carotid bodies (CB) exhibit heightened reflex sensitivity and tonic activity without an apparent stimulus. The mechanisms behind CB sensitization in these conditions are not well understood. METHODS: Guided by functional genomics, a range of functional assays is used to interrogate downstream intracellular and interorgan signaling pathways involved in arterial chemosensory function. RESULTS: Here, we report the presence of the MC4R (melanocortin 4 receptor) in the mammalian CB and show its elevated expression in experimental hypertension. We demonstrate that melanocortin agonists activate arterial chemosensory cells, modulating CB chemosensory afferent drive to influence chemoreflex-evoked sympathetic and ventilatory activity. Transcriptional analysis of hypertensive CB implicates the activation of the Mash1 (mammalian achaete-scute homolog 1; Ascl1 ) regulatory network in driving elevated Mc4r expression. CONCLUSIONS: Collectively, our data indicate a primarily pathophysiological role of melanocortin signaling in arterial chemosensation, contributing to excess sympathetic activity in cardiometabolic disease.